Millipore and Guava Technologies Team Up to Create New Solutions for Cell Biology Market
News Mar 19, 2008
Millipore Corporation and Guava Technologies, Inc. have announced a long-term partnership to deliver integrated flow cytometry solutions to scientists conducting research in cell biology, including stem cell research.
The companies will offer scientists superior technical performance, higher quality data, and much greater accessibility to this powerful analytical platform than is currently available.
Flow cytometry is a technique used by scientists to measure changes in protein expression in individual cells that may occur as a consequence of many important factors such as (stem) cell differentiation, disease, aging, cancer development, drug treatment, and toxicity. The combination of Millipore’s and Guava’s capabilities will integrate instrumentation, reagent kits, validated protocols, and technical support to bring the advantages of flow cytometry to the bench tops of cell biologists.
“Our partnership with Guava creates the potential for us to fundamentally improve the way that cell biology research is conducted,” said Martin Madaus, President & CEO of Millipore.
“The combination of Millipore sample prep and reagents with Guava’s instrument platform will create an integrated offering, giving scientists a menu of plug and play solutions to help them generate high quality results that advance their research. The collaboration allows us to add considerable value to the highly differentiated antibody portfolio and assay development capabilities that came with our Serologicals acquisition.”
Under the terms of the partnership, Millipore will gain exclusive rights to distribute Guava’s non-clinical instrumentation within defined fields in North America, Europe and other countries in Asia.
Additionally, Millipore will provide field service for all Guava instrumentation in the same geographies. Millipore will also develop co-branded reagent kits specifically for Guava’s flow cytometers. Finally, Millipore and Guava Technologies will work together to develop a new generation of instrumentation with enhanced performance and functionality.
“Our two companies have a shared vision of making complex cellular analyses accessible to any scientist. Millipore has significant experience and reach among academic and government researchers and an extensive network of highly qualified service providers throughout the world,” said Lawrence Bruder, President and Chief Executive Officer, Guava Technologies.
“With Millipore as our partner, together we can make this vision a reality and significantly increase our global presence and lower the barriers for cell biologists to adopt flow cytometry as a major research tool,” Bruder added.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.